The U.S. Shouldn’t Use the ‘QALY’ in Drug Cost-effectiveness Reviews

What’s a year of life worth?

That question is at the heart of a metric called the quality-adjusted life year that is increasingly being used to make decisions about paying for new drugs.

If I was asked that question about one of my children, my answer would be “limitless,” and no one could persuade me otherwise. But others are putting a discrete price tag on it.

Read More at STAT

Close Menu